On the other hand, rs3846455G dosage was associated with the expression of certain presynaptic proteins previously reported to be associated with residual cognitive decline in the ROS and MAP cohorts [15]: rs3846455G was associated with lower Complexin-I level (estimated effect = −0.33, 95% CI −0.57 to −0.09, p = 0.0073, FDR = 0.022) but not with Complexin-II level (FDR > 0.05) or Syntaxin/SNAP-25 protein–protein interaction (FDR > 0.05). The gene discussed is CPLX2; the disease is Mental deterioration.